Our applications

What will you achieve with mRNA? Life-changing medicines, vaccines and more made possible by the latest improvements in mRNA and LNP technology.

This page is under construction – please come back soon

Read more about Title

Title

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat

Read more
Read more about Dolor sit amet lorem

Dolor sit amet lorem

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat

Read more
Read more about Title

Title

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat

Read more
Read more about Title

Title

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat

Read more

Examples of what
can be done with mRNA

Novel therapies for rare metabolic disorders

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Corona vaccines

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Next-generation vaccines

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Immuno-oncology

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Last one

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Discovering the function of genes and rescuing knock- downs/knock-outs

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

(trans)Differentiation of (stem)-cells and treatment of organoids

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Targeted therapy for CKD

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

Bone-regeneration

At the moment, the most well-known example of mRNA in the clinical setting is the use as vaccine against SARS-COV-2 (Corona virus). Before these vaccines, no mRNA medicine or vaccine had reached the market, mainly due to the mRNA technology being relatively new. Only recently, a combination of de-immunization of mRNA and improved mRNA-delivery technology, allowed effective use of mRNA.

These Corona vaccines have shown the robust immunological responses when expressing non-self proteins in a manner that mimics a viral infection (non-self proteins produced by autologous proteins). In addition, they proved that mRNA is a relatively easy technology to develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization.

To develop new vaccines with, because mRNA production is robust, regardless of sequence, whereas virus or protein production often require elaborate optimization and characterization. test

Customers

What our customers say

“RiboPro offers not only high-quality mRNA but also very helpful and fast support on all matters concerning mRNA.”

Jana Schembera

Researcher

“We are RiboPro customer since 2020 and we are satisfied about their products. We also appreciate very much the customer service. The team is very cooperative and helpful, communication is clear, precise and always on time.”

Chiara Gai

“RiboPro provided both the expert support and synthesized the high-quality mRNA to make our first gene manipulation experiments a resounding success. Furthermore, RiboPro was able to provide the mRNA constructs at an inordinate speed.”

Aviad Pato

Head of research at Gamida Cell

“I ordered a custom Cap-1 mRNA from RiboPro for in vivo research. The custom mRNA from RiboPro expressed as the target protein in the mammalian cell line and maintained good level of protein expression in vivo (mouse). They delivered me the mRNA product in a timely manner and gave useful comments, responses and transparency to my questions for my order. So, I would recommend users trying the RiboPro.”

Lee Jenny

“The high quality, stable and non-immunogenic mRNA generated by Ribopro is extremely suitable to meet our needs. The company also offers the qualified expert advice allowing the optimization of our experimental protocols.”

Prof. Dr. Elena Levtchenko

Professor at KU Leuven

Interested in mRNA but still having some questions?

Get in contactOr schedule a meeting

Welcome on our new website

Please bear with us while we get everything in order.
Importantly, we are ready to receive your order, quote request or meeting request as per usual.
We look forward helping you with the highest quality mRNA.